CIRIUM
1.12.2022 09:02:37 CET | Business Wire | Press release
Cirium’s analysis of the World Airline Group Finance Rankings results for 2021 and the first half of 2022, shows how the steep decline in airline revenues has translated into a net loss of nearly $220 billion over the past two and a half years since the pandemic began.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005382/en/
Cirium airline group corporate financial results for the first half of 2022. (Photo: Business Wire)
The full extent of damage from the pandemic shows through in the latest Cirium airline rankings. Revenues for the world’s airline groups more than halved in 2020 and, despite some recovery, ended 2021 still down by over 40% on pre-pandemic levels. At $500 billion, revenues remain lower than they were 15 years ago.
With most airline financial results in for the first half of 2022, there are further signs of recovery from the depth of the crisis, but the industry is expected to show another loss for the whole of 2022.
Jeremy Bowen, CEO at Cirium said: “It’s a positive sign that the net deficit is decreasing year-over-year. In 2020, the revenue decline translated into net losses of $160 billion, another $42 billion last year and losses for the first half of this year total around $15 billion.
“If losses so far this year aren’t substantially added to, that would leave the airline industry with the overall net loss of nearly $220 billion since the start of 2020. However, if we assume that there are no further shocks to the industry, there is the possibility that the industry may break even in the second half of the year, led by US and European groups.”
Demand has been recovering, with global revenues up by 70% for the first six months of 2022, bringing the total to within 20% of 2019 levels.
Cirium’s World Airline Group Finance Rankings for the first half of 2022 shows strongest progress from the North American carriers as they marked up a 5% increase over pre-pandemic levels and returned to a modest operating profit.
Delta Air Lines returns to the top of the revenue ranking this year, with revenue virtually back to pre-pandemic levels. The Federal Express (FedEx) air cargo operation narrowly slips to second spot, having led throughout the pandemic thanks to a strong global air freight market, driven by surging demand for PPE and ecommerce.
Early results for the September quarter show the six largest US carriers now with record revenues and an overall net profit for the first nine months of the year, putting the industry on course to post a modest profit for the year if trends continue.
The major European airline groups such as Lufthansa, also showed strong recovery in first half revenues, following the lifting of travel restrictions in early 2022 which unleashed a wave of passenger demand.
Traffic within Western Europe has been running at around 95% of pre-pandemic levels since the middle of the year, raising revenues and returning the largest groups to profitability in the September quarter.
By contrast, the Asia-Pacific region has struggled, largely because of China’s continued COVID-19 lockdowns. Chinese airlines posted a 35% decline in revenue and a net loss of nearly $10 billion in the first half of 2022, higher than either of the previous two years. The results going into the second half of the year look likely to add to that deficit. That is likely to be offset to an extent by airlines within the rest of the region, but on current performance that looks unlikely to be enough to counter the deficit flowing from China.
Rank |
Airline Group |
Country |
Revenue ($m) |
Change (%) |
Op Result |
Operating Margin (%) |
Net Result |
Net Margin (%) |
||||||||||||||||||||||||||||||||||
2022 |
2019 |
2022 |
22 v 21 |
22 v 19 |
|
2022 |
2022 |
2021 |
2020 |
2019 |
2022 |
2022 |
2021 |
2020 |
2019 |
|||||||||||||||||||||||||||
1 |
1 |
Delta Air Lines |
USA |
23,172 |
105 |
% |
1 |
% |
736 |
3 |
% |
-5 |
% |
-52 |
% |
14 |
% |
-205 |
-1 |
% |
-5 |
% |
-62 |
% |
9 |
% |
||||||||||||||||
2 |
5 |
FedEx |
USA |
23,072 |
8 |
% |
23 |
% |
1,599 |
7 |
% |
7 |
% |
2 |
% |
6 |
% |
1,402 |
6 |
% |
7 |
% |
3 |
% |
6 |
% |
||||||||||||||||
3 |
2 |
American Airlines |
USA |
22,321 |
94 |
% |
-1 |
% |
-706 |
-3 |
% |
-8 |
% |
-50 |
% |
7 |
% |
-1,159 |
-5 |
% |
-11 |
% |
-42 |
% |
4 |
% |
||||||||||||||||
4 |
3 |
United Airlines |
USA |
19,678 |
126 |
% |
-6 |
% |
-498 |
-3 |
% |
-19 |
% |
-28 |
% |
9 |
% |
-1,048 |
-5 |
% |
-21 |
% |
-35 |
% |
6 |
% |
||||||||||||||||
5 |
4 |
Lufthansa |
Germany |
16,107 |
108 |
% |
-23 |
% |
-215 |
-1 |
% |
-29 |
% |
-31 |
% |
2 |
% |
-353 |
-2 |
% |
-28 |
% |
-39 |
% |
-1 |
% |
||||||||||||||||
If the industry does manage to contain its net loss for the full year around the $10-15 billion mark, it is worth remembering that is still equivalent to industry annual losses 20 years before in the wake of the crisis that followed the 9/11 attacks.
Cirium’s World Airline Group Passenger Rankings for 2021 and First Half of 2022 is a premium analysis available in Cirium Dashboard. The report features:
- Top 25 airline groups by revenue ($m) Jan-Jun 2022
- Top 100 airline groups by revenue ($m) 2021
- Airline group corporate financial results by region Jan-Jun 2022 ($bn)
- Passenger volumes by region Jan-Jun 2022
- Airline group corporate financial results by region and airline type 2019-2021 ($bn)
Click here to download the full report.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005382/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
